AC Immune is planning to advance its investigational anti-TDP-43 antibody into clinical testing for neurodegenerative diseases in which TPD-43 protein aggregates play a major role in brain damage, including diseases such as Alzheimer’s, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration with TDP-43 pathology. The company began preclinical studies that, if successful, would pave the way for an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking permission to begin the first…
You must be logged in to read/download the full post.
The post AC Immune Moves Closer to Clinical Studies of Anti-TDP-43 Antibody appeared first on BioNewsFeeds.